GTC presented abstracts at ASH 2024
GTC’s posters from 2024 Convention of American Society of Hematology are now available to be downloaded. Please reach out with any questions.
Establishing a Distinct Cytokine Signature for Multiple Myeloma
Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)
Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)
Establishing Lymphoma Type-Specific Cytokine Signatures
Using Tissue-Based RNA or Peripheral Blood Cell-Free RNA (cfRNA)
Clonotype- naive Detection Of Clonality in Patients Suspected of Having Multiple Myeloma or Monoclonal Gammopathy Using Peripheral Blood Cell-Free RNA (cfRNA)
Read more Articles and News from GTC
Using cell free DNA (cfDNA) and RNA (cfRNA) in the diagnosis andmonitoring of primary and metastatic CNS tumors
New Paper Published in The Journal of Liquid Biopsy A B S T R A C T Background: Cerebrospinal fluid (CSF) is a relatively accessible
New Paper Highlights the Critical Role of GTC’s Molecular Testing in CTCL
Dr. Maher Albitar of Genomic Testing Cooperative is among the study’s co-authors. Read the publication in Modern Pathology DOI: 10.1016/j.modpat.2026.101054Published online: August 13, 2026.
Using cell-free RNA to identify B- and T-cell clonality for diagnosis and monitoring of B- and T-cell neoplasms
New Paper published in FEBS openbio Cell-free RNA (cfRNA) is emerging as a supplemental approach for liquid biopsy (LBx). Given that lymphoid cells and plasma
Biology-based multi-class classification of cancer using genomics and artificial intelligence
Abstract Cancer classification traditionally focuses on tissue of origin and histology appearance. Traditional “hard” classification for a specific diagnostic class yields binary yes/no class prediction.